查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836810

核酸检测市场按产品类型、技术、样本类型、应用和最终用户划分－2025-2032 年全球预测

Nucleic Acid Testing Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2032年核酸检测市场规模将成长至84.8亿美元，复合年增长率为10.60%。

主要市场统计数据
基准年2024年 37.9亿美元
预计2025年 41.9亿美元
预测年份：2032年 84.8亿美元
复合年增长率（%） 10.60%

关于技术、监管和资料管治的融合如何再形成各行业核酸检测应用的简明入门

核酸检测已从一项小众实验室技术发展成为临床诊断、生命科学研究和生物防御领域的基础技术。检测化学、样品製备工作流程和数位讯号处理的最新进展提高了分析灵敏度和通量，同时缩短了获得结果的时间。这项转变已将应用范围从集中式分子实验室扩展到即时诊断、分散式临床试验和环境监测倡议。

随着技术的成熟，监管机构日益协调分子检测和平台的验证要求，为临床应用开闢了清晰的路径。同时，开发人员正在整合软体主导的分析技术和云端资料管理，以增强可解释性和合规性。因此，相关人员必须掌握技术能力、监管环境和资料管治交会的格局，以确定新产品惠及病患、研究人员和公共卫生计画的速度。

鑑于这些动态，策略规划人员应专注于互通性、跨不同样本类型的检测稳健性以及试剂和耗材的可扩展生产。同时，投资者和顾问正在评估平台的扩充性、下游资讯服务以及连接实验室和临床工作流程的伙伴关係。对于活跃于核酸检测领域的机构而言，从展示能力到持续的临床效用仍然是一项核心挑战和机会。

模组化仪器、人工智慧主导的分析和供应稳健的试剂策略如何催化分散分子诊断的新时代

随着微型仪器、人工智慧分析和不断扩展的检测化学方法的融合，核酸检测领域正在经历变革。微型化降低了去中心化的门槛，使设备能够以少量样本操作，并简化了工作流程，适用于门诊和患者附近环境。同时，机器学习模型正在整合到讯号处理流程中，以提高准确性、减少假阳性并支援自动化品管，即使在非专家环境下也能获得更可靠的结果。

平台模组化也是一个重要趋势。仪器製造商正在设计具有可更换检测模组和开放式软体架构的仪器，以满足新兴病原体靶点和多重检测需求。这种设计理念有助于快速应对公共卫生威胁，并提高产品生命週期管理的效率。此外，试剂製造商正专注于冷冻干燥化学品和室温稳定套件，以解决不同地区供应链的脆弱性和物流限制。

最后，人们越来越重视整合样本采集、云端基础资料管理和临床决策支援的端到端解决方案。这类综合解决方案提升了软体和服务在传统诊断价值链中的作用，创造了新的经常性收益机会，同时也引发了资料隐私和互通性方面的考量，企业必须积极应对。

定性分析关税政策的变化将如何影响整个分子检测供应链的製造在地化、筹资策略和采购弹性

影响进口检测设备、试剂和耗材的政策调整和关税措施对核酸检测的供应链设计和筹资策略有重大影响。关税上调会增加精密光学元件、聚合酵素连锁反应热迴圈仪和专用酵素等关键零件的到岸成本，进而影响仪器和套件製造商的采购决策。为此，一些供应商正在加快关键製造流程的在地化或寻找合格的替代供应商，以降低跨境关税波动带来的风险。

关税主导的成本压力也促使产品设计发生变化，透过替换零件、整合供应商基础以及转向标准化、在地采购的零件，减少对受关税影响的投入。此类策略转变提高了弹性，但可能需要在检验和品管方面进行前期投资，以确保检测性能不受影响。对于最终用户而言，采购週期正在延长，因为企业不再仅依赖单价，而是考虑整体拥有成本、服务覆盖范围和供应连续性。

此外，政策的不确定性也使得合约保护、双重筹资策略以及关键试剂的库存缓衝更加重要。因此，积极评估关税风险并实施灵活采购和生产方法的相关人员将能够提高市场灵活性，并减少检测工作流程中下游营运的中断。

策略性细分揭示了产品类型、技术模式、样本矩阵、用例、最终应用和最终用户配置文件如何推动商业机会和优先事项

对产品类型动态的洞察揭示了仪器、试剂和套件以及软体和服务的明确需求驱动因素。仪器的采用与处理容量要求和部署偏好密切相关，而试剂和试剂套件则受检测稳健性、储存稳定性和供应连续性的控制。软体和服务正越来越多地透过资料分析、法规支援和工作流程整合来获取价值，从而实现除一次性耗材之外的经常性收益。从技术角度来看，数位PCR和次世代定序仪为复杂应用提供了高灵敏度和多路復用功能，而等温扩增和即时PCR在快速、经济高效的诊断方面仍然具有吸引力。微阵列平台在特定的基因组筛检和研究中仍然具有重要意义，其中预先定义的探针组可提供高效的标靶分析。

样本类型（包括血液、唾液、拭子、组织和尿液）决定了检测设计和使用者体验。基于血液的检测通常优先考虑分析灵敏度和标准化采集，而基于唾液和拭子的方法则优先考虑采集的简易性和稳定性。基于组织和尿液的检测提供独特的诊断窗口，需要客製化萃取和特定基质的验证。临床诊断、药物研发、法医学、研究和兽医诊断等应用领域各自都有独特的监管、通量和数据解读要求，这些要求会影响产品蓝图。最终用户群（包括学术研究机构、诊断实验室、医院和诊所以及製药和生物技术公司）在购买节奏、对法规遵从性的重视程度以及对软体主导的整合解决方案的开放程度方面各不相同。

综合这些细分领域，我们发现，核酸检测的成功取决于产品开发与技术能力、样本製备限制以及每个最终用户的实际操作相结合。因此，产品开发团队应优先考虑模组化平台、可适应不同样本基质的经过检验的工作流程，以及能够同时反映研究型和临床型客户需求的灵活商业模式。

不同地区的基础设施、法律规范和公共卫生重点如何影响产品引进和市场进入的差异化策略

区域动态持续影响着核酸检测相关人员的产品策略和市场进入方式。美洲地区拥有先进的实验室基础设施和灵活的临床网络，这些网络有利于高通量平台、整合的IT系统和全面的监管路径。这种环境支援诸如高精度肿瘤学检测和大容量传染病检查，同时也要求严格的资料安全和报销协调。

欧洲、中东和非洲的市场格局更加多元化，统一的监管环境与不同程度的实验室基础设施并存。在许多欧洲、中东和非洲市场，买家看重的是强大的供应链、稳定的试剂以及能够在多个监管辖区内检验的解决方案。与当地经销商伙伴关係以及在培训和服务物流的投资，有助于克服碎片化问题，并加速其在临床和兽医领域的应用。

在公共卫生重点、本地製造投资以及大规模研究倡议的推动下，亚太地区正在快速采用照护现场和分散式检查解决方案。该地区多样化的医疗保健服务模式需要灵活的产品配置、多语言软体介面和灵活的资金筹措方案。在所有地区，互通性、供应弹性以及与当地监管要求的一致性都是持续进入市场并获得商业性成功的关键考虑因素。

透过平台创新、协作生态系统和优先考虑可重复性、供应弹性和卓越服务的整合策略实现竞争动态

核酸检测领域的公司行为以平台创新、策略伙伴关係和垂直整合相结合为特征。领先的仪器开发人员持续投资于扩展检测选单、提高通量并缩短获得结果的时间，而套件和试剂製造商则专注于配方稳定性和简化的工作流程，以拓宽应用情境。软体和服务供应商正变得越来越重要，他们不断扩展以硬体为中心的产品组合，并透过资料分析、品质保证和法规文件等服务深化客户关係。

协作开发模式尤其突出，诊断开发人员与学术中心、契约製造和软体整合商合作，以加速验证和规模化生产。此类合作有助于分散风险，并缩短复杂检测的上市时间。同时，一些公司正在寻求后向整合以确保关键试剂的供应，并向前整合以提供完整的检测解决方案，包括检体体采集、分析和报告。

竞争优势日益依赖卓越的服务、法规专业知识以及在不同样本类型和实验室环境下提供可重复性能的能力。那些将强大的技术能力与可靠的全球供应链和积极主动的客户支援相结合的公司更有可能在临床、研究和应用诊断领域获得认可。

领导者可以采取切实可行、影响深远的策略措施，以加速采用、增强供应链弹性，并将整合硬体和软体产品收益

为了克服复杂性并实现永续成长，核酸检测领域的领导者应优先考虑几项可行的策略。首先，投资模组化平台架构，以实现快速添加检测试剂盒并轻鬆验证，无论样本类型如何。模组化设计缩短了产品开发时间，从而能够快速回应紧急的公共卫生需求。其次，制定供应链应急计划，包括双重采购、关键部件的本地製造选项以及策略性库存政策，以缓衝关税波动和物流中断的影响。

第三，我们将透过将硬体与云端分析、监管支援服务和培训计画结合，从而增强我们的价值提案，从而减少客户采用过程中的摩擦。此类整合服务将提升客户留存率，并创造持续性收益来源。第四，我们将与学术、临床和製造机构建立有针对性的伙伴关係，以共用验证负担，并加快在分散监管辖区的市场准入。最后，我们将把隐私设计 (privacy-by-design) 和互通性标准纳入我们的软体蓝图，以满足对资料管治和临床整合日益增长的期望。

执行这些优先事项将使公司能够平衡创新速度与临床应用所需的操作严谨性，从而将技术能力转化为持久的市场相关性。

我们的多来源、三角研究途径结合了专家访谈、技术文献和监管讯号，提供了强有力的见解和可操作建议

本研究结合了对仪器製造、试剂开发、临床实验室和监管机构领域意见领袖的定性访谈，以及对同行评审文献、技术白皮书和政策指南的系统性二次分析。调查方法强调透过与已记录的产品规格和已发表的检验研究进行三角检验，对相关人员的观点和见解进行交叉检验。访谈重点在于产品开发蓝图、监管策略、製造依赖关係以及客户采用挑战，分析基于实际营运。

我们使用二级资讯来源，包括试剂和平台技术说明、临床验证报告以及官方监管通报，以确保结论反映检验的性能特征和合规性预期。分析框架将研究结果结构化，涵盖技术模式、样本基质、应用领域和最终用户概况，从而提供针对性建议，以应对清晰的策略决策。最后，由领域专家参与的迭代审查流程确保了解释的严谨性，并降低了偏差风险。

结论性综合强调，需要将卓越的技术与营运弹性和协作商业化结合，以实现持久影响

总而言之，核酸检测正处于曲折点，技术进步、监管日益成熟以及不断变化的采购重点正在重塑诊断产品的开发、验证和交付方式。模组化仪器、灵活的试剂策略和软体驱动的分析技术相互作用，催生了新的商业模式，这些模式註重互通性、跨样本类型的可重复性能以及强大的售后服务能力。相关人员，将最有能力将技术能力转化为临床和商业性效益。

展望未来，公司应将资料管治、侦测稳健性和客户应对力视为其产品价值的核心要素，而非仅供参考。这样做不仅可以提高采用率，还能建立长期融入临床工作流程和公共卫生基础设施所需的组织信任。最终，最成功的公司将是那些将卓越的科学成果与切合实际的营运计划和协作式的上市执行相结合的公司。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 基于 CRISPR 的新兴照护现场平台，用于快速检测多种病原体的核酸
  • 将自动化样本到答案工作流程与微流体实验室晶片集成，实现分散式检查
  • 扩展多重数位 PCR 检测，实现肿瘤学和感染疾病中多个基因标靶的同时定量
  • 采用等温扩增技术，在资源有限的环境中实现更快、无需仪器的病原体筛检
  • 在高通量定序中引入人工智慧驱动的分析，用于即时变异识别和疫情监测
  • 远端医疗和数位健康平台的兴起，导致直接面向消费者的基因和传染病检查服务激增
  • 为了减少人为错误并提高测试吞吐量，对全自动和机器人样品製备解决方案的投资不断增加。
  • 核酸萃取套件和试剂的监管标准化简化了全球供应链和品管

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 核酸检测市场（依产品类型）

  • 装置
  • 试剂和套件
  • 软体和服务

第九章 核酸检测市场（依技术）

  • 数位PCR
  • 等温扩增
  • 微阵列
  • 次世代定序
  • 即时PCR

第十章 核酸检测市场（依样本型态）

  • 血
  • 唾液
  • 棉花棒
  • 组织
  • 尿

第十一章 核酸检测市场（依应用）

  • 临床诊断
  • 药物研发
  • 法医学
  • 研究
  • 兽医诊断

第十二章 核酸检测市场（依最终用户）

  • 学术研究机构
  • 诊断实验室
  • 医院和诊所
  • 製药和生物技术公司

第十三章 核酸检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 核酸检测市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国核酸检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Roche Diagnostics GmbH
    • Thermo Fisher Scientific, Inc.
    • QIAGEN NV
    • Abbott Laboratories
    • Hologic, Inc.
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • PerkinElmer, Inc.
Product Code: MRR-036C5CF3B554

The Nucleic Acid Testing Market is projected to grow by USD 8.48 billion at a CAGR of 10.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.79 billion
Estimated Year [2025] USD 4.19 billion
Forecast Year [2032] USD 8.48 billion
CAGR (%) 10.60%

A concise primer on how technological, regulatory, and data governance convergences are reshaping nucleic acid testing adoption across sectors

Nucleic acid testing has evolved from a laboratory niche to a foundational technology across clinical diagnostics, life sciences research, and biodefense. Recent advances in assay chemistry, sample preparation workflows, and digital signal processing have increased analytical sensitivity and throughput while reducing time to result. This transformation has expanded the range of use cases beyond centralized molecular labs into point-of-care settings, decentralized clinical trials, and environmental surveillance initiatives.

As technologies have matured, regulatory bodies have increasingly harmonized validation expectations for molecular assays and platforms, enabling clearer pathways for clinical adoption. At the same time, developers are integrating software-driven analytics and cloud-enabled data management to enhance interpretability and compliance. Consequently, stakeholders must navigate a landscape where technological capability, regulatory alignment, and data governance converge to determine the pace at which new offerings reach patients, researchers, and public health programs.

Given these dynamics, strategic planners should focus on interoperability, assay robustness across diverse sample types, and scalable manufacturing of reagents and consumables. In parallel, investors and advisors are evaluating platform extensibility, downstream data services, and partnerships that bridge laboratory and clinical workflows. Transitioning from capability demonstrations to sustained clinical utility remains the central challenge and opportunity for organizations active in nucleic acid testing.

How modular instruments, AI-driven analytics, and supply-resilient reagent strategies are catalyzing a new era of decentralized molecular diagnostics

The nucleic acid testing landscape is undergoing transformative shifts driven by the convergence of miniaturized instrumentation, AI-enabled analytics, and expanded assay chemistries. Miniaturization has lowered barriers to decentralization, enabling devices that operate with reduced sample volumes and simplified workflows suitable for outpatient clinics and near-patient settings. Concurrently, machine learning models are being integrated into signal processing pipelines to improve accuracy, reduce false positives, and support automated quality control, thereby enabling higher-confidence results in non-specialist environments.

Platform modularity is another defining trend. Manufacturers are designing instruments with swappable assay modules and open software architectures to accommodate emergent pathogen targets and multiplexed testing needs. This design philosophy supports faster response to public health threats and more efficient product lifecycle management. Additionally, reagent manufacturers are focusing on lyophilized chemistries and room-temperature stable kits to address supply chain fragility and logistical constraints in varied geographies.

Finally, there is a rising emphasis on end-to-end solutions that integrate sample collection, cloud-based data management, and clinical decision support. These holistic offerings are elevating the role of software and services within the traditional diagnostics value chain, creating new recurring revenue opportunities while also raising data privacy and interoperability considerations that organizations must proactively address.

Qualitative analysis of how tariff policy shifts influence manufacturing localization, sourcing strategies, and procurement resilience across the molecular testing supply chain

Policy adjustments and tariff actions affecting imported laboratory equipment, reagents, and consumables have material implications for supply chain design and procurement strategies in nucleic acid testing. Increased tariffs raise the landed cost of key components such as precision optics, thermal cyclers, and specialty enzymes, which in turn influences the sourcing decisions of instrument makers and kit manufacturers. In response, some suppliers accelerate localization of critical manufacturing steps or qualify alternative suppliers to mitigate exposure to cross-border tariff volatility.

Tariff-driven cost pressures also incentivize product redesigns that reduce dependence on tariff-exposed inputs through component substitution, consolidation of supplier bases, or migration to standardized, locally sourced parts. These strategic shifts can improve resilience but may require upfront investments in revalidation and quality management to ensure assay performance remains uncompromised. For end users, procurement cycles are lengthening as organizations weigh total cost of ownership, service coverage, and supply continuity rather than relying solely on unit price.

Moreover, policy uncertainty encourages greater emphasis on contractual protections, dual-sourcing strategies, and inventory buffering for critical reagents. As a result, stakeholders who proactively assess tariff exposure and implement adaptive sourcing and manufacturing approaches enhance their market agility and reduce downstream operational disruptions in testing workflows.

Strategic segmentation reveals how product type, technology modality, sample matrices, application use cases, and end-user realities jointly define opportunity and prioritization

Insight into product type dynamics reveals distinct demand drivers for instruments, reagents and kits, and software and services. Instrument adoption is closely tied to throughput requirements and deployment setting, while reagents and kits are governed by assay robustness, storage stability, and supply continuity. Software and services increasingly capture value through data analytics, regulatory support, and workflow integration, enabling recurring revenue beyond single-use consumables. When examined by technology, digital PCR and next generation sequencing offer high sensitivity and multiplexing capabilities for complex applications, while isothermal amplification and real-time PCR remain attractive for rapid, cost-effective diagnostics. Microarray platforms retain relevance in certain genomic screening and research contexts where predefined probe panels provide efficient target analysis.

Sample type considerations shape assay design and user experience across blood, saliva, swabs, tissue, and urine. Blood-based assays typically prioritize analytical sensitivity and standardized collection, whereas saliva and swab-based approaches emphasize ease of collection and stability. Tissue and urine assays open specialized diagnostic windows that require tailored extraction and matrix-specific validation. Application areas such as clinical diagnostics, drug discovery, forensics, research, and veterinary diagnostics each impose unique regulatory, throughput, and data-interpretation requirements that influence product roadmaps. End-user segments including academic research institutes, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies differ in purchasing cadence, emphasis on regulatory compliance, and openness to integrated software-driven solutions.

Taken together, these segmentation lenses demonstrate that success in nucleic acid testing depends on aligning product development with the intersection of technological capability, sample-preparation constraints, and the operational realities of distinct end users. Product teams should therefore prioritize modular platforms, validated workflows for diverse sample matrices, and flexible commercial models that reflect the needs of both research-focused and clinical-facing customers.

How distinct regional infrastructure, regulatory frameworks, and public health priorities are shaping differentiated strategies for product adoption and market access

Regional dynamics continue to influence product strategies and go-to-market approaches for nucleic acid testing stakeholders. The Americas feature advanced laboratory infrastructure and fast-adopting clinical networks that favor high-throughput platforms, integrated IT systems, and comprehensive regulatory pathways. This environment supports complex applications such as precision oncology assays and high-volume infectious disease testing, while also demanding stringent data security and reimbursement alignment.

Europe, the Middle East and Africa present a more heterogeneous landscape, where pockets of regulatory harmonization coexist with varying levels of laboratory infrastructure. In many EMEA markets, buyers value robust supply chains, reagent stability, and solutions that can be validated across multiple regulatory jurisdictions. Partnerships with local distributors and investments in training and service logistics help overcome fragmentation and accelerate adoption in both clinical and veterinary settings.

Asia-Pacific displays rapid adoption of point-of-care and decentralized testing solutions driven by public health priorities, investments in local manufacturing, and large-scale research initiatives. Diverse healthcare delivery models across the region require adaptable product configurations, multilingual software interfaces, and flexible financing arrangements. Across all regions, interoperability, supply resilience, and alignment with local regulatory expectations remain essential considerations for sustained market access and commercial success.

Competitive dynamics driven by platform innovation, collaborative ecosystems, and integration strategies that prioritize reproducibility, supply resilience, and service excellence

Company behavior in the nucleic acid testing domain is characterized by a mix of platform innovation, strategic partnerships, and vertical integration. Leading instrument developers continue to invest in expanding assay menus, improving throughput, and shortening time to result, while kit and reagent producers focus on formulation stability and simplified workflows to broaden use cases. Software and services providers are increasingly critical, offering data analytics, quality assurance, and regulatory documentation that augment hardware-centric offerings and deepen customer relationships.

Collaborative models are prominent, with diagnostic developers partnering with academic centers, contract manufacturers, and software integrators to accelerate validation and scale production. These alliances help spread risk and reduce time to market for complex assays, particularly when navigating multi-jurisdictional regulatory environments. At the same time, some players pursue backward integration to secure critical reagent supplies or forward integration to offer bundled testing solutions that include sample collection, analytics, and reporting.

Competitive differentiation increasingly rests on service excellence, regulatory expertise, and the ability to deliver reproducible performance across diverse sample types and laboratory settings. Organizations that combine robust technical performance with dependable global supply chains and proactive customer support are best positioned to capture adoption across clinical, research, and applied diagnostic segments.

Practical, high-impact strategic moves for leaders to accelerate adoption, fortify supply chain resilience, and monetize integrated hardware-software offerings

Leaders in nucleic acid testing should prioritize several actionable strategies to navigate complexity and unlock sustained growth. First, invest in modular platform architectures that enable rapid assay additions and ease of validation across sample types. Modular designs reduce product development timelines and allow quicker responses to emergent public health needs. Second, develop supply chain contingency plans that include dual sourcing, local manufacturing options for critical components, and strategic inventory policies to buffer against tariff volatility and logistic disruptions.

Third, enhance value propositions by pairing hardware with cloud-enabled analytics, regulatory support services, and training programs that reduce friction in customer adoption. Such integrated offerings increase stickiness and create recurring revenue streams. Fourth, pursue targeted partnerships with academic, clinical, and manufacturing organizations to share validation burden and accelerate market entry in fragmented regulatory jurisdictions. Finally, embed privacy-by-design and interoperability standards into software roadmaps to meet growing expectations around data governance and clinical integration.

By executing on these priorities, organizations can balance innovation speed with the operational rigor required for clinical adoption, thereby converting technical capability into lasting market relevance.

A multi-source, triangulated research approach combining expert interviews, technical literature, and regulatory signals to ensure robust insight synthesis and actionable recommendations

This research synthesizes primary qualitative interviews with thought leaders across instrument manufacturing, reagent development, clinical laboratories, and regulatory affairs, complemented by systematic secondary analysis of peer-reviewed literature, technical white papers, and policy guidance. The methodology emphasizes cross-validation of insights by triangulating stakeholder perspectives with documented product specifications and published validation studies. Interviews focused on product development roadmaps, regulatory strategies, manufacturing dependencies, and customer adoption challenges to ground analysis in operational realities.

Secondary sources included reagent and platform technical notes, clinical validation reports, and public regulatory communications to ensure that conclusions reflect verifiable performance characteristics and compliance expectations. The analytical framework structured findings across technology modality, sample matrix, application area, and end-user profile, enabling targeted recommendations that map to distinct strategic decisions. Finally, an iterative review process involving subject-matter experts ensured interpretive rigor and reduced the risk of bias, while supplemental sensitivity checks examined alternative scenarios for supply chain and regulatory developments.

A conclusive synthesis that emphasizes the necessity of marrying technical excellence with operational resilience and collaborative commercialization to achieve durable impact

In conclusion, nucleic acid testing sits at an inflection point where technical advances, regulatory maturation, and evolving procurement priorities are reshaping how diagnostics are developed, validated, and delivered. The interplay between modular instrumentation, resilient reagent strategies, and software-enabled analytics is creating new commercial models that reward interoperability, reproducible performance across sample types, and strong post-sale service capabilities. Stakeholders that align product design with regional regulatory realities and invest in supply chain flexibility will be best positioned to translate technical capability into clinical and commercial impact.

Moving forward, organizations should treat data governance, assay robustness, and customer enablement as core elements of product value rather than adjunct considerations. In doing so, they will not only enhance adoption rates but also build the institutional trust necessary for long-term integration into clinical workflows and public health infrastructures. Ultimately, the most successful players will be those who combine scientific excellence with pragmatic operational planning and collaborative go-to-market execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of CRISPR-based point-of-care platforms for rapid nucleic acid detection across diverse pathogens
  • 5.2. Integration of microfluidic lab-on-a-chip systems with automated sample-to-answer workflows for decentralized testing
  • 5.3. Expansion of multiplex digital PCR assays enabling simultaneous quantification of multiple genetic targets in oncology and infectious disease
  • 5.4. Adoption of isothermal amplification technologies in resource-limited settings for faster and equipment-free pathogen screening
  • 5.5. Deployment of AI-driven analytics in high-throughput sequencing for real-time variant identification and outbreak surveillance
  • 5.6. Surge in direct-to-consumer genetic and infectious disease testing services driven by telehealth and digital health platforms
  • 5.7. Rising investment in fully automated robotic sample preparation solutions to reduce human error and increase testing throughput
  • 5.8. Regulatory standardization of nucleic acid extraction kits and reagents to streamline global supply chains and quality control

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Testing Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Nucleic Acid Testing Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Isothermal Amplification
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Nucleic Acid Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Swabs
  • 10.4. Tissue
  • 10.5. Urine

11. Nucleic Acid Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery
  • 11.3. Forensics
  • 11.4. Research
  • 11.5. Veterinary Diagnostics

12. Nucleic Acid Testing Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Roche Diagnostics GmbH
    • 16.3.2. Thermo Fisher Scientific, Inc.
    • 16.3.3. QIAGEN N.V.
    • 16.3.4. Abbott Laboratories
    • 16.3.5. Hologic, Inc.
    • 16.3.6. Bio-Rad Laboratories, Inc.
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Danaher Corporation
    • 16.3.9. Agilent Technologies, Inc.
    • 16.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NUCLEIC ACID TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NUCLEIC ACID TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GCC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GCC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. GCC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GCC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. GCC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. GCC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. G7 NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. G7 NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. G7 NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. G7 NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. G7 NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. G7 NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. G7 NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. G7 NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. G7 NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. G7 NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. NATO NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. NATO NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. NATO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NATO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. NATO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. NATO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. NATO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 317. NATO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. NATO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLIO